222 related articles for article (PubMed ID: 27192055)
21. Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors.
Davis SL; Ionkina AA; Bagby SM; Orth JD; Gittleman B; Marcus JM; Lam ET; Corr BR; O'Bryant CL; Glode AE; Tan AC; Kim J; Tentler JJ; Capasso A; Lopez KL; Gustafson DL; Messersmith WA; Leong S; Eckhardt SG; Pitts TM; Diamond JR
Clin Cancer Res; 2020 Sep; 26(17):4633-4642. PubMed ID: 32414750
[TBL] [Abstract][Full Text] [Related]
22. Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer.
Goff LW; Azad NS; Stein S; Whisenant JG; Koyama T; Vaishampayan U; Hochster H; Connolly R; Weise A; LoRusso PM; Salaria SN; El-Rifai W; Berlin JD
Invest New Drugs; 2019 Apr; 37(2):315-322. PubMed ID: 30191522
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Kelly KR; Shea TC; Goy A; Berdeja JG; Reeder CB; McDonagh KT; Zhou X; Danaee H; Liu H; Ecsedy JA; Niu H; Benaim E; Iyer SP
Invest New Drugs; 2014 Jun; 32(3):489-99. PubMed ID: 24352795
[TBL] [Abstract][Full Text] [Related]
24. Population Pharmacokinetics and Exposure-Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies.
Zhou X; Mould DR; Yuan Y; Fox E; Greengard E; Faller DV; Venkatakrishnan K
J Clin Pharmacol; 2022 Feb; 62(2):206-219. PubMed ID: 34435684
[TBL] [Abstract][Full Text] [Related]
25. Mass balance, routes of excretion, and pharmacokinetics of investigational oral [
Zhou X; Pusalkar S; Chowdhury SK; Searle S; Li Y; Ullmann CD; Venkatakrishnan K
Invest New Drugs; 2019 Aug; 37(4):666-673. PubMed ID: 30397836
[TBL] [Abstract][Full Text] [Related]
26. Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors.
Isambert N; Freyer G; Zanetta S; You B; Fumoleau P; Falandry C; Favier L; Assadourian S; Soussan-Lazard K; Ziti-Ljajic S; Trillet-Lenoir V
Clin Cancer Res; 2012 Mar; 18(6):1743-50. PubMed ID: 22261804
[TBL] [Abstract][Full Text] [Related]
27. ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumors.
Luke JJ; LoRusso P; Shapiro GI; Krivoshik A; Schuster R; Yamazaki T; Arai Y; Fakhoury A; Dmuchowski C; Infante JR
Cancer Chemother Pharmacol; 2016 Mar; 77(3):549-58. PubMed ID: 26811179
[TBL] [Abstract][Full Text] [Related]
28. Alisertib: a review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors.
Liewer S; Huddleston A
Expert Opin Investig Drugs; 2018 Jan; 27(1):105-112. PubMed ID: 29260599
[TBL] [Abstract][Full Text] [Related]
29. Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor.
Niu H; Shin H; Gao F; Zhang J; Bahamon B; Danaee H; Melichar B; Schilder RJ; Coleman RL; Falchook G; Adenis A; Behbakht K; DeMichele A; Dees EC; Perez K; Matulonis U; Sawrycki P; Huebner D; Ecsedy J
EBioMedicine; 2017 Nov; 25():50-57. PubMed ID: 29122619
[TBL] [Abstract][Full Text] [Related]
30. Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies.
Zhou X; Nemunaitis J; Pant S; Bauer TM; Patel M; Sarantopoulos J; Craig Lockhart A; Goodman D; Huebner D; Mould DR; Venkatakrishnan K
Invest New Drugs; 2018 Apr; 36(2):240-247. PubMed ID: 28819760
[TBL] [Abstract][Full Text] [Related]
31. Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study.
Melichar B; Adenis A; Lockhart AC; Bennouna J; Dees EC; Kayaleh O; Obermannova R; DeMichele A; Zatloukal P; Zhang B; Ullmann CD; Schusterbauer C
Lancet Oncol; 2015 Apr; 16(4):395-405. PubMed ID: 25728526
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Dysfunction.
Zhou X; Lockhart AC; Fu S; Nemunaitis J; Sarantopoulos J; Muehler A; Rangachari L; Bargfrede M; Venkatakrishnan K
J Clin Pharmacol; 2019 Sep; 59(9):1204-1215. PubMed ID: 30985952
[TBL] [Abstract][Full Text] [Related]
33. A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.
LoRusso PM; Infante JR; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; Cohen RB
BMC Cancer; 2017 Mar; 17(1):173. PubMed ID: 28264648
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.
Friedberg JW; Mahadevan D; Cebula E; Persky D; Lossos I; Agarwal AB; Jung J; Burack R; Zhou X; Leonard EJ; Fingert H; Danaee H; Bernstein SH
J Clin Oncol; 2014 Jan; 32(1):44-50. PubMed ID: 24043741
[TBL] [Abstract][Full Text] [Related]
35. Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies.
Siddiqi T; Frankel P; Beumer JH; Kiesel BF; Christner S; Ruel C; Song JY; Chen R; Kelly KR; Ailawadhi S; Kaesberg P; Popplewell L; Puverel S; Piekarz R; Forman SJ; Newman EM
Leuk Lymphoma; 2020 Feb; 61(2):309-317. PubMed ID: 31617432
[TBL] [Abstract][Full Text] [Related]
36. A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer.
Chen JA; Huynh JC; Wu CY; Yu AM; Matsukuma K; Semrad TJ; Gandara DR; Li T; Riess JW; Tam K; Mack PC; Martinez A; Mahaffey N; Kelly KL; Kim EJ
Cancer Chemother Pharmacol; 2022 Sep; 90(3):217-228. PubMed ID: 35907014
[TBL] [Abstract][Full Text] [Related]
37. A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer.
Chu FM; Picus J; Fracasso PM; Dreicer R; Lang Z; Foster B
Invest New Drugs; 2011 Aug; 29(4):674-9. PubMed ID: 20145975
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Matulonis UA; Sharma S; Ghamande S; Gordon MS; Del Prete SA; Ray-Coquard I; Kutarska E; Liu H; Fingert H; Zhou X; Danaee H; Schilder RJ
Gynecol Oncol; 2012 Oct; 127(1):63-9. PubMed ID: 22772063
[TBL] [Abstract][Full Text] [Related]
39. Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
Yang JJ; Li Y; Chakravarty A; Lu C; Xia CQ; Chen S; Pusalkar S; Zhang M; Ecsedy J; Manfredi MG; Wu JT; Shyu WC; Balani SK
Drug Metab Lett; 2014 Jul; 7(2):96-104. PubMed ID: 24484538
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.
Dickson MA; Mahoney MR; Tap WD; D'Angelo SP; Keohan ML; Van Tine BA; Agulnik M; Horvath LE; Nair JS; Schwartz GK
Ann Oncol; 2016 Oct; 27(10):1855-60. PubMed ID: 27502708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
